This bill requires Maryland's Office of the Comptroller, with assistance from the Department of Human Services, to conduct a feasibility study on creating a program that would provide monthly payments to caregivers of specific family members. The study will examine economic impacts like potential increases in workforce participation, tax revenue, and reduced reliance on public benefits, while also identifying funding sources and administrative costs. It must be completed by July 1, 2027, and reported to relevant legislative committees. The bill does not establish the program itself but sets the groundwork for evaluating its potential. This study directly affects state agencies responsible for conducting the analysis, with no direct impact on caregivers or families until a future decision to implement the program.
HB 1249 prohibits certified recovery residences in Maryland from refusing services to individuals receiving medication-assisted treatment (MAT) for opioid use disorder or requiring them to stop or change their MAT as a condition for housing. The bill amends certification standards for recovery residences (which provide non-clinical housing for people with substance use disorders) to ensure credentialing entities cannot allow such discrimination. It directly affects certified recovery residences and individuals using MAT for opioid addiction, requiring certification rules to explicitly ban these practices. The law takes effect October 1, 2026, and applies only to opioid use disorder treatment under MAT.
HB 1280 directs Maryland's Comptroller to study whether a program providing monthly payments to caregivers for specific family members would be feasible. The study must examine economic impacts like potential job growth, increased tax revenue, and reduced public benefits use, while assessing costs and funding options. It requires collaboration with the Department of Human Services and agencies like the Department of Aging, with a final report due by July 1, 2027. The bill expires June 30, 2028, and does not create the program itself.
HB 372 requires hospitals with emergency departments to screen patients for emergency pregnancy-related medical conditions (defined as acute conditions posing serious health risks if untreated). If such a condition is identified, hospitals must provide treatment to stabilize the patient - including allowing pregnancy termination when medically necessary - or transfer the patient to another facility. The bill prohibits hospitals from penalizing healthcare providers who refuse to transfer unstable patients or from taking adverse action against staff who report violations. It directly affects hospitals, patients with emergency pregnancy conditions, and healthcare providers treating these cases, with fines up to $50,000 for non-compliance.
HB 6 requires Maryland's public colleges and universities to collect and report data on students' parental status, including whether they are parents, guardians, or caregivers of children. Public institutions must adopt a plan by October 2026 that provides referrals to government assistance programs (like WIC, child care scholarships, and Medicaid), campus accommodations, and health services for pregnant and parenting students. The Maryland Higher Education Commission will collect this data annually starting in 2027 and submit reports to legislative committees. This bill directly affects all students enrolled at Maryland's public higher education institutions (including University System schools, Morgan State, and St. Mary’s College) who are pregnant or parenting.
This bill requires Maryland hospitals to screen patients in emergency departments for pregnancy-related medical emergencies. If a patient has such a condition, hospitals must stabilize it through appropriate treatment - including pregnancy termination when medically necessary - before transferring them, and cannot transfer unstable patients without following federal emergency transfer rules. It prohibits hospitals from retaliating against staff who refuse transfers of unstable patients or report violations, and imposes civil penalties (up to $50,000) for noncompliance. The law applies to all Maryland hospitals and aims to ensure timely, stable care for pregnant patients in medical crises.
HB 625 shifts responsibility for collecting fees from research facilities to the Maryland Department of Agriculture, replacing the current system under the Department of Health. It requires facilities submitting USDA Form 7023 (for animal testing) to pay annual contributions based on animal count: $5,000 for ≤100 animals, $10,000 for 101-500, $55,000 for 501-5,000, and $75,000 for over 5,000. Funds collected will support the Human-Relevant Research Fund established under Maryland’s Economic Development Article. The bill repeals existing health code provisions and creates new agriculture code sections for this fee structure, effective October 2026.
HB 1533 (the Crown and Care Act) bans 12 specific harmful ingredients - including certain phthalates, formaldehyde, mercury, and PFAS chemicals - from cosmetic products sold in Maryland. It directly affects cosmetic manufacturers, retailers, and salons by prohibiting the sale or distribution of products containing these ingredients, with limited exceptions for unavoidable trace amounts from manufacturing processes. The bill authorizes the Maryland Department of Health to investigate complaints, inspect businesses, and enforce penalties, while allowing consumers harmed by violations to seek civil damages and attorney fees. This law aims to protect public health by reducing exposure to chemicals linked to health risks like skin irritation and potential long-term harm.
SB 656 bans 12 specific harmful chemicals in cosmetics sold in Maryland, including formaldehyde, mercury, and certain PFAS chemicals. It creates civil liability for manufacturers or sellers who violate this ban, allowing consumers to sue for damages. The Maryland Department of Health gains authority to investigate complaints, inspect businesses, and collect product samples. The law exempts trace amounts of banned ingredients that occur unavoidably during manufacturing. The bill takes effect July 1, 2026.
SB 773 allows pharmacists in Maryland to order certain vaccinations (like flu, COVID-19, or emergency vaccines) for patients aged 3 and older without needing to administer the vaccine themselves. To qualify, pharmacists must complete 20 hours of approved training, hold current CPR certification, and complete 2 hours of continuing education on immunizations. The bill requires pharmacists to follow written vaccine-specific protocols, report all vaccinations to Maryland’s ImmuNet registry, and refer pediatric patients to primary care providers when appropriate. This policy directly affects pharmacists, patients seeking these vaccines, and healthcare coordination for immunizations. The changes take effect October 1, 2026.
